Although imatinib (Gleevec) has shown ?wonder drug? capabilities for treating chronic myeloid leukemia (CML) and other cancers, a small percentage of patients have relapsed after building a resistance to the drug. Others with advanced cancers have failed to produce durable remissions. A molecular understanding of resistance has rapidly led to the development of a drug that might prove more effective than Gleevec.
Go to Previous Page
Go to Next Page